Spinal muscular atrophies (SMA, also known as hereditary motor neuropathies) and hereditary motor and sensory neuropathies (HMSN) are clinically and genetically heterogeneous disorders of the peripheral nervous system. Here we report that mutations in the TRPV4 gene cause congenital distal SMA, scapuloperoneal SMA, HMSN 2C. We identified three missense substitutions (R269H, R315W and R316C) affecting the intracellular N-terminal ankyrin domain of the TRPV4 ion channel in five families. Expression of mutant TRPV4 constructs in cells from the HeLa line revealed diminished surface localization of mutant proteins. In addition, TRPV4-regulated Ca 2+ influx was substantially reduced even after stimulation with 4PDD, a TRPV4 channel-specific agonist, and with hypo-osmotic solution. In summary, we describe a new hereditary channelopathy caused by mutations in TRPV4 and present evidence that the resulting substitutions in the N-terminal ankyrin domain affect channel maturation, leading to reduced surface expression of functional TRPV4 channels.
Congenital distal SMA (MIM%600175), scapuloperoneal SMA (SPSMA, MIM%181405) and hereditary motor and sensory neuropathy 2C (HMSN2C, MIM%606071) are distinct subtypes of spinal muscular atrophies and hereditary motor and sensory neuropathies characterized by distal and proximal muscle weakness and wasting and by autosomal dominant inheritance. Additional features such as vocal cord paralysis, scoliosis and/or arthrogryposis are likely to occur within families carrying these diseases [1] [2] [3] [4] . Sensory abnormalities have also been described in HMSN2C. Risk loci for congenital distal SMA, SPSMA and HMSN2C have been linked to chromosome 12q23-24 (refs. 2-4) . Although clinically distinct, these disorders show some phenotypic overlap, leading to the suggestion that they may result from mutations in the same gene 4 . Recently, non-neurological diseases have also been linked to the same chromosomal region 5 . We identified a large family (FAM_1; see anonymized pedigree, Supplementary  Fig. 1 ) with ten living individuals showing a mild to severe congenital distal SMA, SPSMA or HMSN2C phenotype. We first carried out a genome-wide scan using 10K SNP Affymetrix arrays on 12 individuals of the family (left branch of the pedigree; Supplementary Fig. 1 ) and observed linkage to three chromosomal regions with log 10 of odds (lod) scores >2 for several SNP markers, including the chromosome 12q23-24 region (data not shown). We constructed haplotypes by including additional distantly related family members (right branch of the pedigree; Supplementary Fig. 1 ). The genetic interval transmitted with the disease resides between SNPs rs2374688 and rs35426 (Chr. 12: 106,197,332-114,054,429 bp; Supplementary Table 1) and overlaps with the intervals reported for risk of congenital distal SMA, SPSMA and HMSN2C [2] [3] [4] .
In an affected individual from family FAM_1, we began sequencing all protein-coding exons and exon-intron boundaries of 19 genes but initially observed only known SNPs (Supplementary Table 2 ). However, sequencing of all protein-coding exons of TRPV4 (transient receptor potential vanilloid 4; chr. 12: 108,705,277-108,755,595; reverse strand) revealed a heterozygous C-to-T nucleotide change at position 943 in exon 6 ( Supplementary Fig. 2a) , which is predicted to cause the substitution of arginine with tryptophan at position 315 of TRPV4 (R315W). We then screened DNA samples from additional families showing one of the phenotypes described above, including Alterations in the ankyrin domain of TRPV4 cause congenital distal SMA, scapuloperoneal SMA and HMSN2C Fig. 2b ). The family afflicted with HMSN2C named A5 in the report of McEntagart et al. 4 carried the same R315W substitution as detected in FAM_1, whereas two other, unreported small families with HMSN2C (here called FAM_3 and FAM_4) carried the C946T transition changing arginine to cysteine at position 316 (R316C) (Supplementary Fig. 2a ). The mutations causing these three substitutions were present in all affected individuals but were not found in 162 (looking at exon 5) and 304 (looking at exon 6) healthy European control individuals. Apparent gain-of-function mutations in TRPV4 have recently been identified in a newly categorized family of autosomal dominant skeletal dysplasias characterized by varying degrees of short trunk and short limbs, ranging from the relatively mild type 3 brachyolmia, through Kozlowski spondylometaphyseal dysplasia, to the more severe metatropic dysplasia 5, 6 . Although many of the affected individuals in our study showed mild to severe scoliosis (Supplementary Table 3) , they did not have a short trunk, short stature, short limbs or brachydactyly. It seems likely that the scoliosis in these families is neuromuscular in etiology and caused by a different pathogenic mechanism. Additional support for a neuromuscular explanation for the scoliosis is provided by the finding that some infants were born with arthrogryposis, a clinical phenotype marked by multiple joint contractures likely resulting from reduced fetal movements in utero. Trpv4-knockout mice show increased bone mass due to reduced bone resorption 7 and have impaired pressure sensation 8 and abnormal osmotic regulation 9 .
The sensory system has been tested extensively in Trpv4 −/− mice 8, 9 . In these animals, the threshold for response to noxious stimuli and the conduction velocity of myelinated nerves responding to stimuli were impaired 8 . The clinical phenotype of the affected individuals described here differs from the phenotypic abnormalities described for Trpv4 −/− mice. Although some of the subjects we examined showed sensory abnormalities, mainly comprising reduced surface sensation, the human disorder much more resembles that of a predominantly motor neuron disease. More detailed studies addressing the function of the motor and sensory nerves in individuals with congenital distal SMA, SPSMA and HMSN2C and in Trpv4 −/− mice might be able to elucidate common neurological abnormalities.
Based on structure and function, the mammalian TRPV family comprises four groups 10 : TRPV1/TRPV2, TRPV3, TRPV4 and TRPV5/TRPV6. The thermosensitive TRPV1, TRPV2, TRPV3 and TRPV4 channels are modestly permeable to Ca 2+ , with a permeability ratio P Ca /P Na between ~1 and ~10 (ref. 11). The first description of TRPV4 and its functional characterization linked it to vertebrate mechanosensation [12] [13] [14] [15] . Mechano-and osmosensory functions of TRPV4 in endothelia, in the alveolar unit of the lung and in intestinal sensory innervation have been subsequently described [16] [17] [18] .
All six TRPV family members share large C-and N-terminal cytosolic domains and a six-transmembrane-segment ion-transport domain ( Fig. 1a) and are presumed to function as tetramers 19 . At their N terminus, the TRPV proteins harbor six ankyrin repeats (ANK) that have been reported to be critical determinants of channel maturation and function in multiple in vitro 24 .
Figure 2
Immunolocalization of wild-type and mutant TRPV4 in transfected HeLa cells. Blue shows artificial coloring of nuclei by Hoechst; green shows anti-His tag staining. Cells were transfected with plasmid DNA (pIRES2-DsRed-Express vector) encoding His 6 -tagged wild-type TRPV4 (hTRPV4), three TRPV4 mutants (R269H, R315W and R316C) and two rescue mutants (R269K and R315K). Cells transfected with hTRPV4 showed localization of the protein to the plasma membrane. Mutants R269H, R315W and R316C were detected as patches distributed over the entire cytoplasm; no staining at the plasma membrane was observed. TRPV4 staining in the rescue mutants R269K and R315K was located predominantly at the plasma membrane. volume 42 | number 2 | february 2010 Nature GeNetics l e t t e r s studies [20] [21] [22] . Crystal structures of the ankyrin repeat domains (ARD) of TRPV1, TRPV2 and TRPV6 have been shown to be highly similar [23] [24] [25] . Each ARD consists of six pairs of antiparallel inner and outer α-helices, followed by a 'finger loop' (Fig. 1b) . The mutations we found resulted in a replacement of highly polar and positively charged arginines (R269H, R315W and R316C) with less polar or nonpolar residues at the outer helices of ANK4 and ANK5 (Fig. 1b) . It is likely that these changes either affect the intrinsic ARD stability or directly abrogate critical protein-protein interactions required for proper TRPV4 channel maturation and function. Also, sequence comparisons of TRPV4 orthologs revealed conservation of each of the arginine residues across multiple vertebrate species, suggesting an important functional role for these residues and a potential pathogenic effect of substitutions (Supplementary Fig. 3) .
To evaluate the consequences of the TRPV4 mutations, we expressed differentially tagged (polyhistidine (His)-or Flag-tagged) mutant and wild-type human TRPV4 in HeLa cells. This cell line did not express any detectable levels of endogenous TRPV4, thereby contrasting it to several batches of HEK293 cells analyzed in our laboratory. Wild-type TRPV4 proteins were predominantly detected at the plasma membrane, whereas mutant TRPV4 proteins formed cytoplasmic aggregates without plasma membrane involvement, as shown by immunofluorescence (Fig. 2) . When cotransfected at equimolar levels, wild-type TRPV4 protein could still be detected at the plasma membrane, but cytoplasmic aggregates were formed by both mutant and wild-type proteins (Fig. 3,  upper) . To exclude adverse effects of cytoplasmic mutant TRPV4 aggregates on HeLa cell viability, we determined membrane permeability as a measure of cell viability. No difference was observed for mutant and wild-type TRPV4 constructs (~15% of the cells were doublepositive for DsRed and YO-PRO-1, indicating unchanged viability; Supplementary Fig. 4a-e) .
Next, we examined the functional properties of HeLa cells transfected with wild-type or mutant TRPV4 channels (Fig. 4) . Calcium-imaging studies revealed no significant differences in basal calcium levels among the transfected cells ( Fig. 4b and  Supplementary Table 4a) . However, cells transfected with wild-type TRPV4 responded with a rapid increase in intracellular calcium when challenged by hypo-osmotic solution, whereas the response of the different mutant TRPV4-transfected cells was significantly lower (P < 0.01) and heterogeneous between the different mutations (Fig. 4a,c and Supplementary Table 4b) . The R269H and R316C mutants showed a significantly decreased (~30%) calcium peak compared to wild-type (Fig. 4c) , whereas the calcium peak of the R315W mutant was decreased by ~75%. When HeLa cells coexpressed wildtype and any of the mutant TRPV4 proteins, we observed no significant change in basal calcium level (data not shown) or response to hypo-osmotic challenge (Fig. 4d and Supplementary Table 4c) .
In patch-clamp studies, the mutant channels yielded significantly (90%, P < 0.001) smaller currents (Fig. 5a-c ) when subjected to a hypo-osmotic challenge (reduction of extracellular osmolarity from 320 to 200 mOsm). Furthermore, activation with the TRPV4-specific agonist 4α-PDD resulted in significantly decreased (P < 0.001) currents in the mutant TRPV4-expressing cells, whereas, as in the Ca 2+ study, cotransfected cells showed a wild-type phenotype (Fig. 5d,e) . Mutant channels could not be activated when cells were shifted to 37 °C (Supplementary Fig. 5 ). The TRPV4 V620I gain-offunction mutant yielded significantly (P < 0.05) increased constitutively activated current and significantly (P < 0.05) elevated response Fig. 6 ) in HeLa cells, as was previously demonstrated in HEK293 cells 5 . Based on our results using HeLa cells as a heterologous expression system, we suggest that the mutations described here lead to decreased stimulus-dependent TRPV4 channel activity. Cell surface biotinylation assays suggested that the functional alterations seen here might result from differences in the levels of surfacedisplayed wild-type and mutant TRPV4 proteins ( Supplementary  Fig. 7 ). Cell surface expression was markedly reduced for the TRPV4 mutants R269H and R315W and was completely abrogated for the R316C mutant.
l e t t e r s after agonist application (Supplementary
TRPV4 protein localization and functionality were restored when the mutated amino acid residues were replaced by lysines (Figs. 2, 3,  4c,d and 5c) , suggesting that site-specific biochemical constraints at positions 269 and 315 are critical for TRPV4 channel localization and function. Previous studies have shown that TRP biogenesis involves protein folding, core glycosylation and oligomerization in the endoplasmic reticulum (ER), followed by transfer to the Golgi network and final transport of the tetramers to the plasma membrane 14, 16, 26 , and that substitutions or deletions in the ARDs result in defective trafficking 19, 20 . Retention and ER-associated degradation have been described for a number of artificial ankyrin domain-deletion TRPV4 mutants or immature and unfolded TRPV4 monomers 21 . Mutations leading to the exposure of di-arginine motifs of type RXR, which are normally concealed within the tetrameric structure, may result in the retention of the misfolded or unfolded proteins within the ER, thereby preventing nonfunctional channel proteins from reaching the cell surface 14, 16, 27 . The TRPV4 protein contains four RXR motifs, two of which are located in the N-terminal ( 122 RWR and 269 RGR) and two in the C-terminal intracellular region of the protein. The arginine missense substitutions R269H, R315W and R316C disrupt one of these repeats, which allowed us to identify a new 315 RR repeat that appears to affect proper TRPV4 channel maturation. The observed TRPV4 alterations are unlikely to interfere with recently published binding sites for ATP, Ca 2+ -calmodulin (corresponding to amino acids 189-222 in TRPV1) 24 and PACSIN3 (amino acids 142-143 in TRPV4), which have been shown to affect channel sensitivity and localization 22 . Interaction with phosphatidylinositol phosphates (PIPs), and in particular phosphatidyl-4,5-bisphosphate (PI(4,5)P 2 ), has been shown to regulate the function of various TRPs 28, 29 . Candidate interaction motifs are pleckstrin homology-like domains, which have been identified as a cluster of positively charged residues. The proposed N-terminal pleckstrin homology-like motif of TRPV4 includes amino acids 114-125 (RHHSSDNKRWRKK) and is thus not directly affected by the mutations identified in this study.
Reduced surface expression accompanied by residual mutant TRPV4 channel activity suggests that the alterations do not directly affect the conductive properties of TRPV4 channels but do have a R269H  R315W  R316C  hTRPV4  R269H  R269K  R315W  R315K  R316C  Control   hTRPV4  hTRPV4  R269H  R269H+  R269H+  R315W+  R315W  R315W+  R316C  R316C+ deleterious impact on channel assembly or trafficking. Based on current knowledge on TRPV channel maturation, we cannot reliably predict how tetramers comprising mutant TRPV4 subunits (that is, with mutant/wild-type ratios of 3:1, 2:2 and 1:3) will behave in surface trafficking and channel function, thus necessitating further studies, both in vitro and in vivo. Compared to the numerous nerve fibers in the healthy peripheral nerve showing intense TRPV4 staining and to the TRPV4 staining pattern of healthy skeletal muscle cells, the pattern seen for the diseased nerve of one subject with HMSN2C (and the R316C substitution) involved less positively stained nerve fibers and weaker cytoplasmic staining of the muscle cells (Fig. 6a-d) .
Haploinsufficiency can be considered the most likely underlying pathomechanism, although we cannot fully exclude adverse interaction of wild-type and mutant TRPV4 subunits. In summary, this work identifies TRPV4 malfunction as the molecular basis for a new channelopathy underlying a heterogeneous group of neurodegenerative disorders. Our findings may lead to improved diagnosis of this diverse group of SMAs and HMSNs and may also contribute to the development of specific treatments.
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We are grateful to the subjects and their families who participated in this study. a PolyChrome V monochromator (Till Photonics) light source in a sealed, temperature-controlled RC-21B imaging chamber (Warner Instruments) and perfused with prewarmed solution (37 °C). Fluorescence images were obtained with alternate excitation at 340 and 380 nm. The emitted light was collected at 510 nm by an air-cooled Andor iXon camera. Measurements were made every 3 s. After 3 min of baseline recording, the cells were perfused with hypoosmotic solution for 5 min, followed by 2 min wash-out with Ringer solution. Background fluorescence was recorded from each cover slide and subtracted before calculation. The acquired images were stored and subsequently processed offline with TILLvisION software (Till Photonics). [Ca 2+ ] i was calculated as described previously 30 . Maximal and minimal ratio values were determined at the end of each experiment by first treating the cells with 1 µM ionomycin (maximal ratio) and then chelating all free Ca 2+ with 10 mM EGTA (minimal ratio). Any cells not responding to ionomycin were discarded. The experiments were repeated at least three times. The average basal calcium level, as well as the hypo-osmotic solution-induced calcium peak of the individual transfected cells, was analyzed (n > 10 in each group) (see Supplementary Note for details on solutions used for Ca 2+ imaging).
Statistical analysis of Ca 2+ imaging and electrophysiology. Numerical values are given as means ± s.e.m. of n cells. Intergroup differences were assessed by a factorial analysis of variance with post hoc analysis with Fisher's least-significant-difference test. P values < 0.05 were considered significant.
Fluorescent-activated cell sorting (FACS) analysis.
To assess whether expression of TRPV4 mutants affects cell viability, HeLa or HEK293 cells were seeded in 12-well plates at 80-90% confluency and transfected the next day with 1.5 µg of pIRES2-DsRed Express (Clontech) vector DNA expressing wild-type TRPV4 or TRPV4 mutants, respectively, using Lipofectamine 2000 (Invitrogen). After 24 h of incubation, cells were harvested and resuspended in cold PBS (4 °C) at a density of 1 × 10 6 cells/ml. The cells were then stained with 1 µl of a 100 µM solution of the membrane-impermeating dye, YO-PRO-1 (Molecular Probes, Invitrogen) on ice for 30 min immediately followed by FACS analysis performed on an LSR II flow cytometer (BD Biosciences) using 488-nm excitation and FACSDiva software (BD Biosciences).
URL. dChip, http://biosun1.harvard.edu/complab/dchip/copy.htm. is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchange. Proc. Natl. Acad. Sci. USA 103, 19093-19098 (2006) .
